Suppr超能文献

表皮生长因子受体(ErbB)异源二聚体中激酶激活剂-受体的偏好性由细胞内区域决定,且与细胞外不对称性无关。

Kinase activator-receiver preference in ErbB heterodimers is determined by intracellular regions and is not coupled to extracellular asymmetry.

作者信息

Ward Matthew D, Leahy Daniel J

机构信息

From the Department of Biophysics and Biophysical Chemistry, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205.

From the Department of Biophysics and Biophysical Chemistry, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205

出版信息

J Biol Chem. 2015 Jan 16;290(3):1570-9. doi: 10.1074/jbc.M114.612085. Epub 2014 Dec 2.

Abstract

The EGF receptor (EGFR) family comprises four homologs in humans collectively known as the ErbB or HER proteins. ErbB proteins are receptor tyrosine kinases that become activated when ligands bind to their extracellular regions and promote formation of specific homo- and heterodimers with enhanced tyrosine kinase activity. An essential feature of ErbB activation is formation of an asymmetric kinase dimer in which the C-terminal lobe of one kinase serves as the activator or donor kinase by binding the N-terminal lobe of a receiver or acceptor kinase and stabilizing its active conformation. ErbB extracellular regions are also thought to form active asymmetric dimers in which only one subunit binds ligand. The observation that the unliganded ErbB2 kinase preferentially serves as the activator kinase when paired with EGFR/ErbB1 implied that extracellular asymmetry in ErbB proteins might be coupled to intracellular asymmetry with unliganded partners favoring the activator kinase position. Using cell-based stimulation assays and chimeric ErbB proteins, we show that extracellular asymmetry is not coupled to intracellular asymmetry and that ErbB intracellular regions are sufficient to determine relative kinase activator-receiver orientation. We further show a hierarchy of activator-receiver preferences among ErbB proteins, with EGFR/ErbB1 being the strongest receiver, followed by ErbB2 and then ErbB4, and that cis-phosphorylation of EGFR and ErbB2 appears to be negligible. This hierarchy shapes the nature of signaling responses to different ligands in cells expressing multiple ErbB proteins.

摘要

表皮生长因子受体(EGFR)家族在人类中包含四个同源物,统称为ErbB或HER蛋白。ErbB蛋白是受体酪氨酸激酶,当配体与其细胞外区域结合时被激活,并促进形成具有增强酪氨酸激酶活性的特定同型和异型二聚体。ErbB激活的一个基本特征是形成不对称激酶二聚体,其中一个激酶的C末端叶通过结合受体或受者激酶的N末端叶并稳定其活性构象,作为激活剂或供体激酶。ErbB细胞外区域也被认为形成活性不对称二聚体,其中只有一个亚基结合配体。未结合配体的ErbB2激酶与EGFR/ErbB1配对时优先作为激活剂激酶,这一观察结果表明,ErbB蛋白的细胞外不对称可能与细胞内不对称相关联,未结合配体的伙伴有利于激活剂激酶的位置。使用基于细胞的刺激试验和嵌合ErbB蛋白,我们表明细胞外不对称与细胞内不对称不相关,并且ErbB细胞内区域足以确定相对激酶激活剂-受体方向。我们进一步展示了ErbB蛋白之间激活剂-受体偏好的层次结构,EGFR/ErbB1是最强的受体,其次是ErbB2,然后是ErbB4,并且EGFR和ErbB2的顺式磷酸化似乎可以忽略不计。这种层次结构塑造了表达多种ErbB蛋白的细胞中对不同配体的信号反应的性质。

相似文献

2
The ErbB/HER family of protein-tyrosine kinases and cancer.
Pharmacol Res. 2014 Jan;79:34-74. doi: 10.1016/j.phrs.2013.11.002. Epub 2013 Nov 20.
4
Mechanics of EGF receptor/ErbB2 kinase activation revealed by luciferase fragment complementation imaging.
Proc Natl Acad Sci U S A. 2012 Jan 3;109(1):137-42. doi: 10.1073/pnas.1111316109. Epub 2011 Dec 21.
5
Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Pharmacol Res. 2019 Jan;139:395-411. doi: 10.1016/j.phrs.2018.11.014. Epub 2018 Nov 27.
6
ErbB2 and ErbB3 do not quantitatively modulate ligand-induced ErbB4 tyrosine phosphorylation.
Cell Signal. 2002 Sep;14(9):793-8. doi: 10.1016/s0898-6568(02)00019-0.
7
A single ligand is sufficient to activate EGFR dimers.
Proc Natl Acad Sci U S A. 2012 Jul 3;109(27):10861-6. doi: 10.1073/pnas.1201114109. Epub 2012 Jun 14.
8
ErbB Receptors and Cancer.
Methods Mol Biol. 2017;1652:3-35. doi: 10.1007/978-1-4939-7219-7_1.
10
ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors.
Pharmacol Res. 2014 Sep;87:42-59. doi: 10.1016/j.phrs.2014.06.001. Epub 2014 Jun 11.

引用本文的文献

1
Trans-activating mutations of the pseudokinase ERBB3.
Oncogene. 2024 Jul;43(29):2253-2265. doi: 10.1038/s41388-024-03070-9. Epub 2024 May 28.
3
Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma.
Ther Adv Med Oncol. 2023 Jan 12;15:17588359221138377. doi: 10.1177/17588359221138377. eCollection 2023.
4
An Unbiased Functional Genetics Screen Identifies Rare Activating ERBB4 Mutations.
Cancer Res Commun. 2022 Jan 7;2(1):10-27. doi: 10.1158/2767-9764.CRC-21-0021. eCollection 2022 Jan.
5
Expanding the Disorder-Function Paradigm in the C-Terminal Tails of Erbbs.
Biomolecules. 2021 Nov 14;11(11):1690. doi: 10.3390/biom11111690.
6
7
Kinetics of receptor tyrosine kinase activation define ERK signaling dynamics.
Sci Signal. 2020 Aug 18;13(645):eaaz5267. doi: 10.1126/scisignal.aaz5267.
8
Mechanisms of Receptor Tyrosine-Protein Kinase ErbB-3 (ERBB3) Action in Human Neoplasia.
Am J Pathol. 2019 Oct;189(10):1898-1912. doi: 10.1016/j.ajpath.2019.06.008. Epub 2019 Jul 25.
9
Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations.
Cancer Cell. 2018 Nov 12;34(5):792-806.e5. doi: 10.1016/j.ccell.2018.09.010. Epub 2018 Oct 25.
10
Molecular dynamics simulations of asymmetric heterodimers of HER1/HER2 complexes.
J Mol Model. 2017 Dec 26;24(1):30. doi: 10.1007/s00894-017-3544-0.

本文引用的文献

1
Mechanism for activation of mutated epidermal growth factor receptors in lung cancer.
Proc Natl Acad Sci U S A. 2013 Sep 17;110(38):E3595-604. doi: 10.1073/pnas.1220050110. Epub 2013 Sep 9.
2
Quantification of cell surface proteins with bispecific antibodies.
Protein Eng Des Sel. 2013 Oct;26(10):645-54. doi: 10.1093/protein/gzt035. Epub 2013 Aug 19.
3
Receptor tyrosine kinases with intracellular pseudokinase domains.
Biochem Soc Trans. 2013 Aug;41(4):1029-36. doi: 10.1042/BST20130104.
5
Functional isolation of activated and unilaterally phosphorylated heterodimers of ERBB2 and ERBB3 as scaffolds in ligand-dependent signaling.
Proc Natl Acad Sci U S A. 2012 Aug 14;109(33):13237-42. doi: 10.1073/pnas.1200105109. Epub 2012 Jun 25.
6
A single ligand is sufficient to activate EGFR dimers.
Proc Natl Acad Sci U S A. 2012 Jul 3;109(27):10861-6. doi: 10.1073/pnas.1201114109. Epub 2012 Jun 14.
8
Mechanics of EGF receptor/ErbB2 kinase activation revealed by luciferase fragment complementation imaging.
Proc Natl Acad Sci U S A. 2012 Jan 3;109(1):137-42. doi: 10.1073/pnas.1111316109. Epub 2011 Dec 21.
9
Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein.
J Biol Chem. 2011 May 27;286(21):18756-65. doi: 10.1074/jbc.M110.206193. Epub 2011 Mar 30.
10
Structural evidence for loose linkage between ligand binding and kinase activation in the epidermal growth factor receptor.
Mol Cell Biol. 2010 Nov;30(22):5432-43. doi: 10.1128/MCB.00742-10. Epub 2010 Sep 13.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验